Day One Biopharmaceuticals (DAWN) Expected to Announce Quarterly Earnings on Tuesday

Day One Biopharmaceuticals (NASDAQ:DAWN) is anticipated to issue its Q3 2025 results after the market closes on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $38.2030 million for the quarter. Parties may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, November 4, 2025 at 4:30 PM ET.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.06. Day One Biopharmaceuticals had a negative return on equity of 19.01% and a negative net margin of 50.63%.The firm had revenue of $33.91 million for the quarter, compared to the consensus estimate of $35.55 million. On average, analysts expect Day One Biopharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Day One Biopharmaceuticals Stock Up 5.7%

Shares of NASDAQ:DAWN opened at $7.44 on Friday. The business’s 50 day moving average is $7.27 and its 200 day moving average is $6.92. The stock has a market cap of $762.08 million, a P/E ratio of -7.83 and a beta of -1.26. Day One Biopharmaceuticals has a 52-week low of $5.64 and a 52-week high of $16.76.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Adam Dubow sold 4,365 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $6.77, for a total transaction of $29,551.05. Following the sale, the insider owned 54,858 shares of the company’s stock, valued at approximately $371,388.66. This trade represents a 7.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeremy Bender sold 16,058 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $6.77, for a total value of $108,712.66. Following the sale, the chief executive officer directly owned 161,365 shares in the company, valued at $1,092,441.05. This trade represents a 9.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 28,295 shares of company stock worth $191,557 over the last quarter. Insiders own 6.20% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

Institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Day One Biopharmaceuticals by 6.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,992 shares of the company’s stock worth $302,000 after purchasing an additional 2,149 shares in the last quarter. Man Group plc raised its stake in shares of Day One Biopharmaceuticals by 46.1% during the 2nd quarter. Man Group plc now owns 56,862 shares of the company’s stock valued at $370,000 after buying an additional 17,950 shares during the last quarter. Nebula Research & Development LLC raised its stake in shares of Day One Biopharmaceuticals by 6.2% during the 2nd quarter. Nebula Research & Development LLC now owns 60,665 shares of the company’s stock valued at $394,000 after buying an additional 3,533 shares during the last quarter. Invesco Ltd. raised its stake in shares of Day One Biopharmaceuticals by 47.6% during the 2nd quarter. Invesco Ltd. now owns 68,507 shares of the company’s stock valued at $445,000 after buying an additional 22,083 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Day One Biopharmaceuticals by 44.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 89,102 shares of the company’s stock valued at $579,000 after purchasing an additional 27,566 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on DAWN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research report on Thursday. Piper Sandler started coverage on Day One Biopharmaceuticals in a research report on Monday, August 18th. They set an “overweight” rating and a $25.00 price target on the stock. HC Wainwright dropped their price target on Day One Biopharmaceuticals from $36.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Needham & Company LLC dropped their price target on Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Finally, Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 13th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $25.29.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.